| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 3.71B | $ 2.25B | $ 1.83B | $ 1.04B | $ 844.29M |
| Gross Profit | $ 3.04B | $ 1.92B | $ 1.52B | $ 868.60M | $ 704.14M |
| Operating Income | $ 501.58M | $ -176.88M | $ -282.18M | $ -785.07M | $ -708.65M |
| EBITDA | $ 631.44M | $ -178.85M | $ -258.24M | $ -926.56M | $ -661.56M |
| Net Income | $ 313.75M | $ -278.16M | $ -440.24M | $ -1.13B | $ -852.82M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 2.91B | $ 2.69B | $ 2.44B | $ 2.19B | $ 2.44B |
| Total Assets | $ 4.97B | $ 4.24B | $ 3.83B | $ 3.55B | $ 3.64B |
| Total Debt | $ 1.28B | $ 1.30B | $ 1.31B | $ 1.32B | $ 997.59M |
| Net Debt | $ -378.86M | $ 329.62M | $ 492.70M | $ 453.85M | $ 177.62M |
| Total Liabilities | $ 4.18B | $ 4.17B | $ 4.05B | $ 3.70B | $ 3.06B |
| Stockholders' Equity | $ 789.18M | $ 67.09M | $ -220.64M | $ -158.22M | $ 588.20M |
| Cash Flow | |||||
| Free Cash Flow | $ 465.38M | $ -42.59M | $ 41.95M | $ -613.33M | $ -718.07M |
| Operating Cash Flow | $ 524.08M | $ -8.31M | $ 104.16M | $ -541.27M | $ -641.69M |
| Investing Cash Flow | $ 436.33M | $ -116.84M | $ -336.35M | $ 169.35M | $ -273.30M |
| Financing Cash Flow | $ -305.19M | $ 294.16M | $ 172.13M | $ 425.75M | $ 1.25B |
Alnylam Pharmaceuticals (DE:DUL)
XETRA:DUL
